Supernus Pharmaceuticals | SUPN - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Abbott USD 6.8B 1.72B 2026-03
ANI Pharmaceuticals USD 311.18M 25.59M 2026-03
Aurora Cannabis CAD 56.36M 39.33M 2025-12
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Canopy Growth CAD 371.32M 73.26M 2025-12
Cara Therapeutics USD 20.73M 684K 2025-12
Corcept Therapeutics USD 108.74M 11.76M 2026-03
Eisai JPY 301.65B 16.27B 2025-09
Eli Lilly USD 5.28B 1.99B 2026-03
Novo Nordisk A/S DKK 18.44B 5.78B 2025-06
Pacira USD 144.31M 14.24M 2026-03
Perrigo USD 531.6M 99.5M 2025-12
Pfizer USD 1.7B 561M 2026-03
Supernus Pharmaceuticals USD 184.87M 56.42M 2026-03
United Therapeutics USD 1.28B 277.4M 2026-03
Xeris Pharmaceuticals USD 111.75M 708K 2026-03